Short answer: Empagliflozin has a half-life of about 12.4 hours. Levels peak about 1.5 hours after a dose. People vary, so treat these as estimates.
Empagliflozin is an SGLT2 inhibitor: it makes the kidneys pass more sugar into the urine. It is sold as Jardiance, a once-daily tablet approved for type 2 diabetes, heart failure and chronic kidney disease.
Also known as: Jardiance.
Jardiance comes as 10 mg and 25 mg tablets.
The FDA Jardiance label approves it to lower the risk of heart-related death and hospital stays in adults with heart failure; to slow kidney decline in adults with chronic kidney disease; to lower the risk of heart-related death in adults with type 2 diabetes and heart disease; and, with diet and exercise, to improve blood sugar in adults and children 10 and older with type 2 diabetes. The label dose is 10 mg once a day in the morning, with or without food; for blood sugar it may be raised to 25 mg. It is not for blood sugar control in type 1 diabetes, or for blood sugar when eGFR is below 30.
Its first listed serious risk is ketoacidosis, which can happen with near-normal blood sugar. The label says to stop it at least 3 days before surgery or long fasting if possible; low food intake and ketogenic diets are listed among the triggers. It can also cause dehydration and low blood pressure, genital yeast infections and urinary infections. See the Jardiance side effects and missed dose pages.
The FDA Jardiance label gives an apparent terminal half-life of about 12.4 hours and peak levels 1.5 hours after a dose. A high-fat meal lowered the peak by about 37% and total exposure by about 16%, which the label does not consider clinically relevant.
Numbers shown are taken from the source above. Half-life varies from person to person.
How Dose Track handles peptides · Reconstitution calculator · Half-life calculator